Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials

References

• Liguigli W , Tomasello G , Toppo L , Ratti M , Passalacqua R . Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial. Future Oncol. 2014;10(9):1549–57.
   PubMed Web of Science ®Google Scholar
• Fuchs CS , Tomasek J , Yong CJ , Dumitru F , Passalacqua R , Goswami C . Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.
   PubMed Web of Science ®Google Scholar
• Wilke H , Muro K , Van Cutsem E , Oh SC , Bodoky G , Shimada Y . Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov: List results, search of ramucirumab. Available from http://clinicaltrials.gov/ct2/results?term=ramucirumab (accessed 2014 Sep 20).
   Google Scholar
• Hapani S , Chu D , Wu S . Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10(6):559–68.
   PubMed Web of Science ®Google Scholar
• Qi WX , Sun YJ , Tang LN , Shen Z , Yao Y . Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2014;89(3):394–403.
   PubMed Web of Science ®Google Scholar
• Garon EB , Ciuleanu TE , Arrieta O , Prabhash K , Syrigos KN , Goksel T . Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73.
   PubMed Web of Science ®Google Scholar
• Penson RT , Moore KM , Fleming GF , Braly P , Schimp V , Nguyen H . A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014;134(3):478–85.
   PubMed Web of Science ®Google Scholar
• Jadad AR , Moore RA , Carroll D , Jenkinson C , Reynolds DJ , Gavaghan DJ . Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Lane PW . Meta-analysis of incidence of rare events. Stat Methods Med Res. 2012;22(2):117–32.
   PubMed Web of Science ®Google Scholar
• DerSimonian R , Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
   PubMedGoogle Scholar
• Mackey JR , Ramos-Vazquez M , Lipatov O , McCarthy N , Krasnozhon D , Semiglazov V . Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol. 2015;33(2):141–8.
   PubMed Web of Science ®Google Scholar
• Tabernero J , Yoshino T , Cohn AL , Obermannova R , Bodoky G , Garcia-Carbonero R . Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499–508.
   PubMed Web of Science ®Google Scholar
• Doebele RC , Spigel D , Tehfe M , Thomas S , Reck M , Verma S . Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2014;6(10):29132.
   Google Scholar
• Saif MW , Elfiky A , Salem RR . Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007;14(6):1860–9.
   PubMed Web of Science ®Google Scholar
• Kamba T , Tam BY , Hashizume H , Haskell A , Sennino B , Mancuso MR . VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290(2):H560–76.
   PubMed Web of Science ®Google Scholar
• Wang Y , Fei D , Vanderlaan M , Song A . Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335–45.
   PubMedGoogle Scholar
• Mir O , Mouthon L , Alexandre J , Mallion JM , Deray G , Guillevin L . Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst. 2007;99(1):85–6.
   PubMed Web of Science ®Google Scholar
• Heinzerling JH , Huerta S . Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg. 2006;63(5):334–7.
   PubMedGoogle Scholar
• Choi YI , Lee SH , Ahn BK , Baek SU , Park SJ , Kim YS . Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat. 2008;40(1):33–5.
   PubMedGoogle Scholar
• Tol J , Cats A , Mol L , Koopman M , Bos MM , van der Hoeven JJ . Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs. 2008;26(4):393–7.
   PubMed Web of Science ®Google Scholar
• Han ES , Monk BJ . What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol. 2007;105(1):3–6.
   PubMed Web of Science ®Google Scholar
• Badgwell BD , Camp ER , Feig B , Wolff RA , Eng C , Ellis LM . Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19(3):577–82.
   PubMed Web of Science ®Google Scholar
• Burger RA , Brady MF , Bookman MA , Monk BJ , Walker JL , Homesley HD . Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2014;32(12):1210–7.
   PubMed Web of Science ®Google Scholar
• Tanyi JL , McCann G , Hagemann AR , Coukos G , Rubin SC , Liao JB . Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol. 2011;120(3):464–9.
   PubMed Web of Science ®Google Scholar
• Sliesoraitis S , Tawfik B . Bevacizumab-induced bowel perforation. J Am Osteopath Assoc. 2011;111(7):437–41.
   PubMedGoogle Scholar
• Walraven M , Witteveen PO , Lolkema MP , van Hillegersberg R , Voest EE , Verheul HM . Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis. 2011;14(2):135–41.
   PubMed Web of Science ®Google Scholar
• Abu-Hejleh T , Mezhir JJ , Goodheart MJ , Halfdanarson TR . Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14(4):277–84.
   PubMed Web of Science ®Google Scholar
• Ezzedine S , Bege T , Berdah S , Vitton V , Grimaud JC , Barthet M . Endoscopic management of colonic perforation owing to angiogenesis inhibitors. Surg Laparosc Endosc Percutan Tech. 2013;20(6):e230–2.
   Google Scholar